Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II ) (BRAINSAFEII)
Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda: A Single Arm Open Label Trial, BRAIN SAFE II
Sponsor: Columbia University
This PHASE3 trial investigates Sickle Cell Anemia in Children and is currently completed. Columbia University leads this study, which shows 10 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
May 2025 — Present [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 5 earlier versions
-
Jun 2022 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
-
Apr 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Oct 2021 — Apr 2022 [monthly]
Recruiting PHASE3
-
Apr 2021 — Oct 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Columbia University
- Emory University
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Global Health Uganda LTD
- Makerere University
- Mulago Hospital, Uganda
- University of Pittsburgh
For direct contact, visit the study record on ClinicalTrials.gov .